Selection of significant genes via expression patterns is an important problem in microarray experiments. Owing to small sample size and the large number of variables (genes), the selection process can be unstable. This paper proposes a hierarchical Bayesian model for gene (variable) selection. We employ latent variables to specialize the model to a regression setting and uses a Bayesian mixture prior to perform the variable selection. We control the size of the model by assigning a prior distribution over the dimension (number of significant genes) of the model. The posterior distributions of the parameters are not in explicit form and we need to use a combination of truncated sampling and Markov Chain Monte Carlo (MCMC) based computation techniques to simulate the parameters from the posteriors. The Bayesian model is flexible enough to identify significant genes as well as to perform future predictions. The method is applied to cancer classification via cDNA microarrays where the genes BRCA1 and BRCA2 are associated with a hereditary disposition to breast cancer, and the method is used to identify a set of significant genes. The method is also applied successfully to the leukemia data.
INTRODUCTION
cDNA microarrays provide expression measurements for thousands of genes at once (Duggan et al., 1999; Schena et al., 1995) . A key goal of gene selection via different expression patterns is to identify the responsible genes for certain events (say, certain diseases or certain types of tumors). The inherent power of expression data to separate * To whom correspondence should be addressed.
sample types was first clearly demonstrated by clustering samples on the basis of gene expression patterns. Microarray problems can be classified as unsupervised, when only the expression data are available, and supervised, when a response measurement is available for each sample. In unsupervised problems the goal is mainly to identify distinct sets of genes with similar expressions, suggesting that they may be biologically related. Supervised and unsupervised problems also focus on finding sets of genes that, for example, relate to different kinds of diseases, so that future tissue samples can be correctly classified. Traditional statistical methods for clustering and classification have been extensively applied to microarray data, see Eisen et al. (1998) ; Alizadeh et al. (2000) for clustering and Golub et al. (1999) and Hedenfalk et al. (2001) for classification. In the supervised case a Bayesian approach to dimension reduction with a probit model has been applied by West et al. (2000) where unlike selecting actual genes, the singular-value decomposition is applied to the design matrix to reduce the dimension of the problem. In this paper we mainly want to identify (select) the important genes which are significantly more influential than the others for the classification process and therefore focus on variable selection.
In many published studies, the number of selected genes is large, for instance, 495 genes (Khan et al., 1998) and 2000 genes (Alon et al., 1999) . Even in studies that obtained smaller numbers of genes, the numbers are excessive for the small number of sample points (microarrays), for instance 50 genes (Golub et al., 1999) or 96 genes (Khan et al., 2001) . A large number of genes in conjunction with a small sample size is not advisable because it can create an unreliable selection process (Dougherty, 2001) . Dudoit et al. (2000) have proposed a method for the identification of singly differentially expressed genes by considering a univariate testing problem for each gene and then correcting for multiple testing using adjusted p-values. Tusher et al. (2001) have proposed Significance Analysis of Microarray (SAM), which assigns a score to each gene on the basis of change in gene expression relative to the standard deviation of repeated measurements. Given the genes with scores greater than an adjustable threshold, SAM uses permutations of the repeated measurements to estimate the percentage of genes identified by chance. Hastie et al. (2000) have suggested gene shaving, a new class of clustering methods that tries to identify subsets of genes with coherent expression patterns with large variation across conditions. Kim et al. (2002) have proposed analytically designing low-dimension linear classifiers from a probability distribution resulting from spreading the mass of the sample points to make classification more difficult, while maintaining sample geometry. The algorithm is parameterized by the variance of the spreading distribution. By increasing the spread, the algorithm finds gene sets whose classification accuracy remains strong relative to greater spreading of the sample.
In this paper we suggest a model-based approach to the variable selection problem. Rather than fixing the dimension (the number of selected genes), we assign a prior distribution over it. The approach creates additional flexibility by allowing the imposition of constraint, such as not allowing the dimension to be too big (say not more than 8) by using this prior. The prior can work as a penalty to create constraint. We use a Markov Chain Monte Carlo (MCMC; Gilks et al., 1996) based stochastic search algorithm that discovers important genes. Given that the model space is very large, as with p genes (say p = 3000) we have 2 p models, exhaustive computation over this model space is not possible. MCMC based stochastic search algorithms, less greedy and more efficient than most other existing algorithms are therefore successfully implemented to identify significant genes. We consider the model for binary events only, assuming there are only two categories of events; extension to multi-category data is done recently by Sha (2002) .
We will consider a data set from Hedenfalk et al. (2001) comparing the expression profiles of hereditary breast cancers where we want to identify genes that can discriminate between BRCA1 and BRCA2 breast cancers. The idea is to identify a small number of genes (by penalizing the dimension) having the greatest discriminating power, thereby allowing researchers to quickly focus on the most promising candidates for diagnostics and therapeutics. This same data set was used in Kim et al. (2002) , and we will point out some similarities between the resulting gene lists. We also use our method on a larger leukemia data set from Golub et al. (1999) to show its predictive power over an independent test set.
MODEL FOR GENE SELECTION
We consider binary responses as Y i = 1 indicates that the tumor sample i is BRCA1 and Y i = 0 indicates that it is BRCA2, for i = 1, . . . n. For each sample we measure expression levels for a set of genes, so X i j is the measurement of the expression level of the jth gene for the ith sample where
We assume that Y i has an independent binary distribution so that Y i = 1 with probability p i , independently of the other Y j , j = i. Then we relate the gene expression level with the response using a probit regression model which yields
where X i is the ith row of the matrix X (vector of gene expression levels of the ith sample), β is the vector of regression parameters (β j is the regression parameter corresponding to the jth gene) and is the normal cumulative distribution function. Albert and Chib (1993) introduced n independent latent variables Z 1 , · · · , Z n with Z i ∼ N (X i β, 1) and where
The latent variable has a linear model form as
In order to perform the variable selection we define γ to be a p × 1 vector of indicator variables with ith element γ i such that γ i = 0 if β i = 0 (the gene is not selected) and γ i = 1 if β i = 0 (the gene is selected). Given γ , let β γ consist of all nonzero elements of β and let X γ be the columns of X corresponding to those elements of γ that are equal to 1. To complete the hierarchical model we need make the following prior assumptions:
(1) Given γ , the prior for
where c is a positive scale factor specified by the user. Smith and Kohn (1996) suggested to choose c between 10 to 100 for linear model problems after extensive testing. We will fix it to a large value as c = 100, in that for this value the prior of β γ , given γ , contains very little information about β γ compared to the likelihood.
(2) The γ i are assumed to be a priori independent with Pr(γ i = 1) = π i , 0 ≤ π i ≤ 1, for i = 1, . . . , p. We will choose the values π i to be small, therefore restricting the number of genes in the model. Prior knowledge that some genes are more important than others can be implemented easily by assigning larger or smaller values of π in a scale of importance from 0 to 1. This prior allows also to model interactions among the genes. Small values of π will indirectly prevent the number of selected genes in the model from being too large.
COMPUTATION
The posterior distribution is not available in explicit form and we therefore use the MCMC method (Gilks et al., 1996) specifically Gibbs sampling (Gelfand and Smith, 1990) to generate the parameters from the posterior distributions.
Our unknowns are (Z , β, γ ) and in order to implement the Gibbs sampling we need to simulate from the complete conditional distributions. Rather than drawing from the complete conditionals we will modify the algorithm and draw γ from the marginal distribution (integrating β out) which will speed up the computations. It can be shown that this modified Gibbs sampler still leaves the target posterior distribution invariant. So our computation scheme will be as follows:
(i) Draw from γ |Z , the marginalized conditional distribution obtained after integrating β out (this is conditionally independent of Y ). Now
where β γ is integrated out as normal integral. The proof is a simple application of Bayesian linear model theory (Lindley and Smith, 1972; Denison et al., 2002) and provided as supplementary information in our web site http://stat.tamu.edu/people/faculty/bmallick.html. Then the conditional distribution is
Rather than drawing γ as a vector, it is better to draw component wise from p(
−1 and index γ means all the elements only corresponding to γ = 1.
(iii) The full conditional distribution of Z i is as follows:
truncated at the right by 0
The distribution of Z is a truncated normal, so its random number generating algorithm follows Robert's (1995) optimal exponential accept-reject algorithm.
After suitable burn-in period (usually 10 000) we obtain the MCMC samples at the tth iteration as {β (t) , Z (t) , γ (t) , t = 1, . . . , m}. We can use this samples from the posterior distributions for posterior inference and prediction.
The Algorithm Start with initial values
Increase t until the required number of iterations.
Stop
For decision making we can calculate the relative number of times that each gene appeared in the sample (number of times the corresponding γ is 1). This will give us an estimate of the posterior probability of inclusion of the single gene as a measure of the relative importance of the gene for classification purpose.
Also we can obtain the predictive classification of a new observation Y new , conditioning on the expression levels as
The Monte-Carlo estimate of this probability will bê
and it can be easily evaluated using normal CDF.
APPLICATION OF GENE SELECTION TO HEREDITARY BREAST CANCER DATA
We apply the proposed strategy for discovering significant genes to a published data set (Hedenfalk et al., 2001) on breast tumors from patients carrying mutations in the predisposing genes, BRCA1 or BRCA2 or from patients not expected to carry a hereditary predisposing mutation. Pathological and genetic differences appear to imply different but overlapping functions for BRCA1 and BRCA2. In Hedenfalk et al. (2001) , cDNA microarrays were used in conjunction with classification algorithms to show the feasibility of using differences in global gene expression profiles to separate BRCA1 and BRCA2 mutation-positive breast cancers. They examined 22 breast tumor samples from 21 breast cancer patients, and all patients except one were women. Fifteen women had hereditary breast cancer, 7 tumors with BRCA1 and 8 tumors with BRCA2. 3226 genes were used for each breast tumor sample. We use our method to classify BRCA1 versus the others (BRCA2 and sporadic). We used a two-sample t-statistics to identify the starting values, say the 5 most significant genes. We then ran the MCMC sampler, in particular, the Gibbs sampling approach fixing π i = 0.005 for all i = 1, 2, . . . , p.
The chain moved quite frequently and we used 50 000 iterations after a 10 000 burn-in period. Table 1 lists the most significant genes as those with the largest frequencies.
We note that the three leading genes in Table 1 appear among the six strongest genes in an analogous list in Kim et al. (2002) . This has occurred even though the rating in the latter paper is based upon the ability of a gene to contribute to a linear classifier, which is quite different than the criterion here. The leading gene in Table 1 is keratin 8 (KRT8), which also leads the list of strong genes in Kim et al. (2002) . It is a member of the cytokeratin family of genes. Cytokeratins are frequently used to identify breast cancer metastases by immunohistochemistry, and cytokeratin 8 abundance has been shown to correlate well with node-positive disease (Brotherick et al., 1998) . The gene TOB1 is second in Table 1 , and appeared fifth in Kim et al. (2002) . It interacts with the oncogene receptor ERBB2, and is found to be more highly expressed in BRCA2 and sporadic cancers, which are likewise more likely to harbor ERBB2 gene amplifications. TOB1 has an anti-proliferative activity that is apparently antagonized by ERBB2 (Matsuda et al., 1996) . We note that the gene for the receptor was not on the arrays, so that the gene-selection algorithm was blinded to its input. Lastly, the third gene in Table 1 appears as the sixth gene in the list of Kim et al. (2002) .
We check the model adequacy in two ways. (i) Cross validation approach: we excluded a single data point (leave-one-out cross validation) and predicted the probability of Y = 1 for that point using Equation (1). We compared this with the observed response and most of the cases obtained almost perfect fitting: 0 classification errors (number of misclassified observations).
(ii) Deviance: Deviance calculation is a criterion-based method measuring the goodness of fit (McCullagh and Nelder, 1989) . Lower deviance means better fit. We calculated the probabilities and the deviance measures for the different models in Table 2 , showing their adequacy:
Model 1 : Using all strong significant genes. Model 2 : Using genes with frequencies more than 5%. Model 3 : Using genes with frequencies more than 6%. Model 4 : Using genes with frequencies more than 7%. We compared our cross validation results with other popular classification algorithms including feed forward neural networks, k-nearest neighbors, support vector machines (SVM). Results are in Table 3 . All other methods have used 51 genes (which we think is too many with respect to a sample size of 22) which may produce instability in the classification process. Our procedure has used a much less number of genes though the results are competitive to any other method. 
Sensitivity analysis
We have checked the sensitivity (stability) of our analysis to the measurement of expression levels (as they are always subject to measurement errors) by adding Gaussian noise to the expression values. We re-analyzed the data contaminated by different levels of Gaussian noise to obtain the newly selected genes and have reproduced the results in Table 4 . The table shows that the analysis is quite stable, as it is selecting almost similar genes under different noise levels over the expression values. Among the seven leading genes in Table 1 , the following appear across all noise conditions in Table 4 : Keratin 8, 'phosphofructokinase platelet,' Selenophosphate synthetase, and butyrate response factor 1. TOB1 is only omitted at the highest noise level.
To check the prior sensitivity we have re-run our algorithm for several choices of c between 10 and 100 and the results are not that sensitive towards the choice of c. We suggest to fix a large value of c (say 100) as it is almost a non-informative prior. The number of selected genes are very sensitive towards the choice of π . On average the number of genes selected will be m × π where m is the total number of genes. For our case m = 3226 and sample size is only 23. With this small sample size we do not want to select too many genes (not more than 23) and we can restrain the number of selected genes by choosing π to be small. For example if we want to keep the number of selected genes around 23 the choice of π should be 0.007. This way the Bayesian method penalizes the number of selected genes through the help of the prior specifications. We re-analyzed the data for several choices of π from 0.001 to 0.1 which selects different number of genes in different cases, but the identification of the frequently arising genes remained the same. A heat map of the identified genes is provided in Figure 1 on a website containing the figures associated with this paper http://stat.tamu.edu/people/faculty/ bmallick.html.
APPLICATION TO LEUKEMIA DATA
We have applied our method to a larger data set containing a test set where we can perform our predictive validation. The leukemia data set is described in Golub et al. (1999) . Bone marrow or peripheral blood samples are taken from 72 patients with either myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Following the experimental setup of the original paper, the data is split into a training set consisting of 38 samples of which 27 are ALL and 11 are AML, and a test set of 34 samples, 20 ALL and 14 AML. The data set contains expression levels for 7129 human genes produced by Affymetrix high-density oligonucleotide microarrays. The scores in the dataset represent the intensity of gene expression after being rescaled to make overall intensities. Golub et al.
(1999) used a predictor trained using their weighted voting scheme on the training samples, and correctly classified all samples for which a prediction is made, 29 of the 34, declining to predict for the other five.
We performed our analysis with the same choices of the hyper-parameters as in the first example and report here our results. In Table 5 we provide the genes which appeared more frequently in our posterior samples. There are several genes, including the top one, that also belong to the set of 50 genes used by Golub et al. (these genes are reported with asterisks in Table 5) .
We used the genes that appeared more than 2.5% of times (appeared to be the top 5 genes) to perform predictions on the test data. The prediction results are reported in Table 6 . Only one observation is misclassified (the observation number 29). These results appear to improve predictions made by Golub et al. (1999) and use only 5 genes rather than 50. Figure 2 on the web site shows the heat map of the 28 genes identified by our method.
A heat map of the identified genes is provided in Figure 2 on the previously mentioned website containing the figures associated with this paper. 
DISCUSSION
We have proposed a Bayesian model for variable selection with binary data and used it to identify important genes using their expression levels. We have used a hierarchical probit model and MCMC based stochastic search techniques to obtain the posterior samples.
Here we have fixed the π value but we can extend our model assuming π is is an unknown model parameter and assigning to it a conjugate beta prior.
We have assumed that the genes are independent though in our framework we can easily extend the model to the dependent case. For example: knowledge of the fact that if the ith gene is expressed the jth gene will be expressed too can be included in our model through the prior distribution on γ . Rather than taking all the γ i as independently distributed we can use a Markov model whose transition matrices will be defined as p(γ j = 1|γ i = 1) or so. This type of problem will be handled in future research. In this paper we have considered binary data. Extension to more than two categories using multinomial models can be found in Albert and Chib (1993) and development of a variable selection model in that setup is in Sha (2002) .
SUPPLEMENTARY DATA
Supplementary data are available on Bioinformatics online.
